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Renal cell carcinoma (RCC) responds very poorly to chemo- or radiotherapy. Renal cell carcinoma cell lines have been described to
be resistant to apoptosis-inducing stimuli and to lack caspase expression. Here, we provide a structural and functional assessment of
the apoptosome, the central caspase-activating signalling complex and a candidate for apoptosis-inactivating mutations. Cells from
RCC cell lines and clinical samples isolated from RCC patients were included. Apoptosome function was measured as quantitative
activation of caspases in protein extracts. In all five cell lines and in 19 out of 20 primary clear cell RCC samples, the expression of
apoptosome components and caspase activation appeared normal. Of the four nonclear cell RCC that could be included, both
oncocytomas gave no response to cytochrome c (in one case, no Apaf-1 was detected), one chromophobe RCC lacked caspase-9
and failed to activate caspase-3 in response to cytochrome c, and one papillary RCC showed good caspase activation despite the lack
of caspase-7. Experiments utilising a peptide derived from Smac/DIABLO gave no indication that inhibitor of apoptosis proteins might
exert an inhibiting effect in primary clear cell RCC. Thus, the apoptosome signalling complex is intact in human (clear cell) RCC, and
an apoptosis defect must be located at other, probably upstream, sites.
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With its incidence varying significantly among countries, renal
cell carcinoma (RCC) accounts for about 2% of all cancer
cases worldwide (Motzer et al, 1996). Metastatic disease is
often present at the time of diagnosis of RCC, and its poor
response to radio- and chemotherapy determines its
poor prognosis. Renal cell carcinoma is a heterogeneous disease
and is classified by a combination of histopathology, histochem-
istry and molecular genetics. The majority of cases fall under the
definition of clear cell carcinomas (also called conventional
carcinomas, Kovacs et al, 1997, about 80%), followed by about
14% of papillary (¼chromophilic) carcinoma (both probably
originating from the proximal tubule) and about 3% of
chromophobic carcinoma. The entity of renal oncocytic adenoma
is considered a benign neoplasm (for review, of RCC, see Motzer
et al, 1996).
Current understanding of tumorigenesis assumes that a
multistep process of changes leads to the development of
cancer. A number of ‘traits’ have been recognised as likely
important in this process (Hanahan and Weinberg, 2000); these
are among others a deregulation of cellular replication and an
evasion of apoptosis (Hanahan and Weinberg, 2000; Green
and Evan, 2002). Cell death by apoptosis occurs when the
intracellular apoptotic pathway is activated, a conserved
signal transduction system (Vaux and Strasser, 1996). Signals
inducing apoptosis can be very diverse and encompass the direct
stimulation of certain plasma membrane molecules (especially
the so-called death receptors), the lack of stimulation through
receptors (growth factor withdrawal, serum starvation) or less
well-defined insults such as treatment with chemicals or irradia-
tion, commonly referred to as ‘cellular stress’ (for review see Vaux
and Strasser, 1996; Green and Evan, 2002). A great number of
details are known about the signal transduction of apoptosis (see
below).
The data are unequivocal on the finding that experimental
inhibition of apoptosis can contribute to tumour development, as
first demonstrated 15 years ago. Although the inhibition of
apoptosis by itself is normally not sufficient to cause tumours,
experimental prevention of apoptosis in mice could massively
contribute to tumour development when proliferation was
concomitantly enhanced (Vaux et al, 1988; Strasser et al, 1990).
This indicates that apoptosis serves as a defence mechanism to
avoid tumour development. The ability to evade apoptosis, which
may result from genetic alterations, will thus enhance the cell’s
propensity to malignancy. Evasion of apoptosis is conceivable on a
number of levels, from changes in the perception of signals to
mutations in the apoptotic pathway proper. Many components and
principles of the apoptosis system are known. The core of the
pathway consists of proteases of the caspase family. Caspase-3 (to
a lesser extent caspases-6 and -7) serves to cleave cellular protein
substrates and thereby to bring about the apoptotic phenotype.
Caspase-3 can either be activated directly by caspase-8 (upon
caspase-8 activation through death receptors) or by a signalling
complex referred to as ‘apoptosome’, consisting of cytochrome c,
Apaf-1, caspase-9 (Li et al, 1997) and, at least sometimes, the X-
linked inhibitor of apoptosis protein (XIAP; Bratton et al, 2001). In
the apoptosome, cytochrome c serves to allow oligomerisation of
Apaf-1 and thereby of caspase-9. Caspase-9 is activated in this
process (Li et al, 1997; Zou et al, 1999). X-linked inhibitor of
apoptosis protein has the potential to inhibit active caspase-3 and
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scan thus halt or slow down the process at this step (Bratton et al,
2001). Cytochrome c is normally sequestered in the mitochondria
of the cell. Its release into the cytosol during apoptosis is thus a
crucial step of the apoptotic signal transduction. Although it is still
not entirely clear how this release is regulated, the role of members
of the Bcl-2 protein family in this process is well established
(Adams and Cory, 2001; Kuwana et al, 2002). Three functionally
different classes within this family of these proteins are known,
apoptosis-inhibiting proteins (for instance, Bcl-2 itself), proteins
that effect the release of cytochrome c (Bax and Bak) and a group
of structurally relatively distant family members, the so-called
BH3-only proteins (Huang and Strasser, 2001). A number of
theories about the molecular function of these proteins in
apoptosis have been put forward. The arguably most promising
(although likely incomplete) model at present is that apoptotic
stimuli activate one or more BH3-only proteins that then activate
Bax/Bak, which in turn effect the release of cytochrome c (by a
mechanism that is not understood). Bcl-2-like proteins in this
model protect against apoptosis by sequestering active BH3-only
proteins. For a recent discussion of this subject see Newmeyer and
Ferguson-Miller (2003).
It has been demonstrated that a set of cell lines derived from
human RCC almost completely lacked the expression of caspase-3
and expressed further caspases only to low levels (Kolenko et al,
1999). This suggested that loss of the expression of central caspases
was a common feature in RCC, an alteration that might be
expected to contribute to RCC development.
The present study was undertaken to follow-up on this finding
in both cell lines and, more importantly, primary tumour material.
We focused here on the analysis of the ‘apoptosome’ in these cells.
Since inactivating mutations will not necessarily be apparent when
only the presence of a protein is analysed, we also assayed the
functional competence of this signalling complex. Cells and cell
extracts were prepared from tumour material and normal kidney
tissue that had been freshly isolated from patients undergoing
nephrectomy for RCC. The expression of the components of the
apoptosome as well as the response to cytochrome c were analysed,
and the inhibitory potential of endogenous inhibitor of apoptosis
proteins (IAP) was assessed.
MATERIALS AND METHODS
Cell lines and isolation of primary cells
The following human cell lines were from the tumour bank at the
Deutsches Krebsforschungszentrum Heidelberg, Germany:
KTCTL-1M, KTCTL-26A, KTCTL-30 (all clear cell carcinoma)
and KTCTL-84 (sarcomatoid carcinoma). CAKI-1 (clear cell
carcinoma) was from ATCC (Rockville, MD, USA). Cells were
cultured in complete Click’s RPMI supplemented with 5% FCS,
5m M glutamine and antibiotics in plastic culture dishes. At about
80% confluency, cultures were split into fresh plates. Primary cells
were obtained from freshly explanted kidneys from patients
undergoing nephrectomy for tumour treatment. In all, 24 patients
(10 female, 14 male, age range 47–81 (median age 69) years) were
included. The study was approved by the Klinikum rechts der Isar
(Technical University Munich) ethics committee and patients gave
their written consent to the use of their tumour tissues for research
purposes. Diagnoses were: two oncocytomas, one papillary
carcinoma (grading G1), one chromophobe carcinoma (G2) and
20 clear cell carcinomas (12 G2, eight G3). Both macroscopically
normal and malignant tissue samples (about, 1g each) were
excised within 1h of nephrectomy. Cells were isolated by
collagenase digestion (3mgml
 1 collagenase in complete Click’s
RPMI at a volume/weight ratio of 3) for 2–3h at 371C on a rocker.
The resulting cell suspension was passed through a metal mesh
(200mm width) and washed three times in complete medium. Cells
were layered in a medium onto a discontinuous Biocoll gradient
(Biochrome, Berlin; two phases: 75 or 100% in PBS) and
centrifuged for 30min at 400g. The fraction at the medium–75%
interface was used for experiments (in some cases, when not
enough cells could be recovered from this step, cells from the 75 to
100% interface were also included). An aliquot from these cells was
spun on glass slides, stained (May–Gru ¨nwald and Giemsa) and
evaluated microscopically. Composition of the preparation was
assessed by microscopy. Only tumour samples that contained at
least 70% of discernible intact tumour cells (20 out of a total of 36
tumours processed) were included in the study (the remainder
being stroma cell, debris and cells whose morphology had been
distorted in the process so as to make a cytologic diagnosis
impossible).
Extract preparation
Cells were washed in PBS and resuspended in extraction buffer (S-
100 buffer: 20mM HEPES-KOH (pH 7.5), 10mM KCl, 1.5mM
MgCl2,1 m M Na–EDTA, 1mM Na–EGTA, supplemented with
2m M DTT and a protease inhibitor cocktail (Roche, Mannheim,
Germany)) at 10
8 cellsml
 1. Cells were lysed by one cycle of
freeze–thawing (liquid nitrogen, thawing at room temperature)
and lysates were cleared by centrifugation at 41C at 10000g for
10min. Protein concentration was measured as absorption at
280nm (it was normally around 50mgml
 1). Extracts were stored
at  801C.
Caspase activation by cytochrome c
Reactions were set up in 40ml and contained 20mgml
 1 extract
protein in S-100 buffer supplemented with 2mM DTT and dATP
(1mM). To some aliquots cytochrome c was added to 1 or
50mgml
 1, and reactions were incubated at 371C for 1h. After this
incubation, the induced effector caspase activity was measured as
the activity that cleaved the fluorigenic caspase peptide substrate
Ac-Asp-Glu-Val-Asp-7-amido-4-methyl-coumarin (DEVD-AMC).
For this assay, triplicate reactions were run in a 96-well flat-
bottom plate and contained 10ml of the above mixture and 90mlo f
reaction buffer (50mM NaCl, 2mM MgCl2,4 0 m M b-glyceropho-
sphate, 5mM EGTA, 0.1% CHAPS, 100mgml
 1 BSA, 10mM HEPES
(pH 7.0), 10mM (final concentration) DEVD-AMC). Reactions were
incubated at 371C and measurements for free AMC were taken
over 40min at 5 or 10min intervals. Linear regression analysis was
performed of the maximum increase of AMC fluorescence (during
the first 5–20min after the addition of DEVD-AMC). The slope of
the resulting straight line was considered effector caspase activity.
As a standard, a sample of extract prepared from the epitheloid cell
line HeLa was included in every experiment (always from the same
batch of HeLa extract). Results for kidney cell samples are given as
percentage of this standard.
Immunoblotting
An aliquot (10ml, corresponding to 200mg of total protein) of the
cytochrome c-induced reaction was boiled in Laemmli buffer, run
on 12% SDS–PAGE, and proteins were transferred onto a
nitrocellulose membrane. The following primary antibodies were
used for protein detection: anticaspase-3 (Pharmingen No.
556425), anticaspase-7 (Pharmingen No. 66871A), anticaspase-9
(Pharmingen No. 68086E), anti-APAF-1 (Pharmingen No. 68076E)
and anti-b-actin (Sigma). Secondary antibodies were peroxidase-
labelled anti-mouse or anti-rabbit goat antibodies (Jackson labs).
Blots were developed using a chemiluminescence reaction (Perkin-
Elmer). The expression of caspases/Apaf-1 was judged visually
from blots that contained the same amount of protein of total HeLa
cell extract alongside RCC samples. Semiquantitative assessment of
expression was as follows: (0) no detectable expression; (1) levels
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sless than; (2) levels equal to; and (3) levels higher than in HeLa
cells. Caspase processing by cytochrome c was judged from the
ratio of procaspase and mature caspase on Western blots.
Semiquantitative values were allocated as follows: (0) no proces-
sing detectable; (1) processed caspase visible but no visible loss of
procaspase; (2) decrease in the signal of the procaspase band
visible; and (3) procaspase completely disappeared.
Measurement of the inhibitory activity of IAP
A synthetic peptide corresponding to the seven N-terminal amino
acids from the mitochondrial IAP inhibitor Smac/DIABLO
(AVPIAQK; Chai et al, 2000; peptides were custom synthesised
at Thermo Hybaid, Ulm, Germany) was added to the extracts.
Incubation with cytochrome c and detection of caspase activity
were performed as above. The assay was validated by titrating
bacterially expressed GST-XIAP (the vector was a kind gift from Dr
David Vaux, Melbourne) against the DIABLO peptide and a
control peptide of the same sequence, but the reverse orientation
(KQAIPVA).
RESULTS
Caspase activation by cytochrome c in cell lines from RCC
In the initial step, we analysed the integrity of the apoptosome in
five RCC cell lines that had originally been established from
separate human tumours (four clear cell RCC, one sarcomatoid
carcinoma). As it has been reported for other RCC cell lines, these
cells showed very little apoptosis when treated with classical
apoptosis-inducing agents such as staurosporine, when compared
for instance to HeLa cells (data not shown). It was our purpose not
only to test for the presence of its components, but also for the
proper function of the apoptosome. We therefore prepared protein
extracts from the cells and investigated the capacity of exogenously
added cytochrome c to activate caspases in these extracts in vitro.
In this experimental system, apoptosome formation and the
activation of caspase-9, -3, -6 and -7 occur very likely in the same
fashion as they would upon the release of cytochrome c from the
mitochondria in intact cells (Liu et al, 1996; Zou et al, 1999). The
induction and detection of caspase activity in this approach
therefore allows the assessment of the integrity of the apoptotic
apparatus downstream of cytochrome c release. As a standard of a
normal apoptosome extracts from the well-investigated human cell
lines, HeLa (epitheloid) or Jurkat (T cell) were prepared and
assayed in parallel.
The expression of caspase-3, -7 and -9 as well as Apaf-1 was
normal by this criterion in all five cell lines as investigated by
Western blotting (data not shown). Upon incubation of the
extracts in the presence of cytochrome c, DEVD-cleaving (effector
caspase) activity was detectable in all cases, and processing of
caspase-3, -7 and -9 was observed in extracts from all five cell lines
(Figure1B and Table 1). The sensitivity towards cytochrome c
appeared to be somewhat different between the cell lines, but they
all gave a good reaction (i.e. caspase activation) at high
concentrations of cytochrome c (Figure 1A). Apoptosome forma-
tion and function appears thus to be normal in the RCC cell lines
investigated.
Cytochrome c-induced caspase activation in primary renal
cells
Taken together, the above results suggested that, in the cell lines
investigated, the formation and activation of the apoptosome were
normal. We then turned to the investigation of these parameters in
human primary RCC. The protocol we devised was the following:
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Figure 1 Composition and function of the apoptosome in five RCC cell
lines. (A) Extracts from five RCC cell lines were incubated for 1h at 371C
in the presence of cytochrome c (one (filled bars) or 50 (open bars)
mgml)
 1. Then, DEVD-cleaving activity was measured as release of AMC
from the effector caspase-substrate DEVD-AMC (see Materials and
Methods for details of the method). Columns give means and s.d. of the
results from three separate experiments, each with separately prepared
extracts. (B) The presence and activation of caspase-3 in RCC cell line
extracts, extracts from the T-cell line Jurkat for comparison. Extracts were
incubated with cytochrome c as above, and caspase-3 and b-actin were
detected by immunoblotting (200mg of total protein per lane was loaded).
Filled arrow, procaspase-3, open arrows, processed caspase-3. Results for
caspase-3, -7 and -9 are summarised in Table 1.
Table 1 Summary of caspase processing induced by cytochrome c in extracts from RCC cell lines
KTCTL-26A KTCTL-30 CAKI-1 KTCTL-1M KTCTL-84A
Cytochrome c (mgml
 1) 1 50 1 50 1 50 1 50 1 50
Caspase-3 0/1/1 2/1/2 1/1/2 2/2/2 1/1/1 2/1/2 1/1/1 2/2/2 1/1/1 1/2/1
Caspase-9 1/2 3/3 3/3 3/3 2/3 3/3 3 3 2/2 3/3
Caspase-7 1/3/3 3/3/3 3/3/3 3/3/3 3/3/3 3/3/3 3/3/3 3/3/3 2/3/1 3/3/3
Extracts from five RCC cell lines were incubated in the absence of cytochrome c or in the presence of 1 or 50mgml
 1 cytochrome c for 1h at 371C. Reactions were then tested
by immunoblotting for processing of caspase-3, -7 and -9. Semiquantitative values were allocated as follows: (0) no processing detectable; (1) processed caspase visible but no
visible loss of procaspase; (2), decrease in the signal of the procaspase band visible; and (3), procaspase completely disappeared. Experiments were performed three times for
caspase-3 and -7, one or two times for caspase-9. Each value represents one separate experiment.
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swhen patients underwent nephrectomy, samples of both macro-
scopically normal and tumourous tissues were collected within 1h
of explantation. From these samples, cells were isolated and the
quality of the cell preparation was controlled by staining and
microscopical assessment. Extracts were prepared immediately
following the isolation of the cells. The histopathologic composi-
tion of samples included was: clear cell carcinoma, 20 cases;
papillary carcinoma, one case; chromophobe carcinoma, one case;
and oncocytoma (nonmalignant), two cases. At the same time, cells
were isolated by the same protocol from nontumourous tissue (five
cases; referred to as normal cells).
In one sample from normal tissue no detectable DEVD-cleaving
activity was induced by cytochrome c addition. Renal cell
carcinoma material form the same patient (#65) was also defective
in caspase activation (see below, Table 3). We were unable to
determine the reason for this. Unfortunately, not enough material
was available from this sample to repeat the experiment or to test
the expression of Apaf-1. One possibility that would explain the
lack of cytochrome c-driven caspase activation is a reduced
expression of Apaf-1. It is also conceivable (although there is no
evidence for this) that a technical problem during the preparation
of the sample is responsible.
In extracts from the remaining four samples both activity and
caspase processing could be detected to varying degrees with only
one peculiarity: in one tissue sample, no caspase-7 was detected by
immunoblotting while strong DEVD-cleaving activity was induced
(Table 2).
Somewhat surprisingly, there was no detectable defect in the
expression and function of the apoptosome in extracts from clear
cell RCC. Of the 20 isolates of which we had obtained satisfactory
Table 2 Induction of DEVD-cleaving activity and caspase processing induced by cytochrome c in normal kidney cells
Caspase-3 Caspase-7 Caspase-9 Apaf-1
Patient DEVD-cleaving activity* (% standard) Expr. Proc. Expr. Proc. Expr. Proc. Expr.
#65 0.8 ++ 0 +++ 0 + 0 NT
#66 38.8 ++ 2 + 3 + 1 NT
#70 65.0 ++ 1 + 2 ++ 2 ++
#71 197.9 ++ 2   0+ + 2+ +
#78 32.0 + 2 + 2 + 2 NT
Extracts from five samples of isolated normal kidney cells were incubated with cytochrome c (50mgml
 1) as above for 1h at 371C. DEVD-cleaving activity was measured and is
shown as percent of HeLa cell extract control. Processing of caspases and the presence of Apaf-1 in extracts was assessed by immunoblotting. Semiquantitative assessment of
processing was as follows: (0) no detectable expression; (1) levels less than; (2) levels equal to; and (3) levels higher than in HeLa cells (see also Materials and Methods). NT¼not
tested. *DEVD-cleaving activity, effect of caspase activity (see Methods).
Table 3 Summary of caspase processing and effector caspase activity induced by cytochrome c in extracts from primary RCC samples
Caspase-3 Caspase-7 Caspase-9
Apaf-1
Patient # Tumour DEVD-cleaving activity* (% standard) Expr. Proc. Expr. Proc. Expr. Proc. Expr.
36 cc 85.2 ++ 1 + 3 + 2 +
38 cc 101.1 ++ 2 + 3 + 2 +
40 cc 123 + 2 + 3 + NT +
43 cc 85.3 + 2 + 3 + NT +
45 cc 116.4 ++ 2 + 3 + 3 +
47 cc 31.4 + 1 NT NT NT NT +
48 cc 34.5 + 2 NT NT NT NT +
49 cc 102.7 ++ 3 NT NT NT NT +
51 cc 87.1 ++ 2 NT NT NT NT +
54 cc 35.9 ++ 2 + 3 + 3 +
55 cc 30.7 ++ 2 + 2 + 3 +
57 cc 41.1 ++ 2 + 2 + 3 NT
62 cc 25.3 ++ 1 + 1 + 3 NT
64 cc 47.6 + 2 NT NT NT
65 cc 2.0 ++ 0 NT NT NT
71 cc 59.5 + 2 + 2 + 3 +
75 cc 69.3 + 2 NT NT +
76 cc 90.7 +++ 2 + 3 + NT +
77 cc 53.1 ++ 2 + 3 ++ NT +
78 cc 56.4 ++ 2 + 3 ++ NT +
Nonclear cell
32 cp 3.55 + 0 + 0   0+
39 oc 0.7 + 0 + 0 + 0  
41 oc 1.2 + 0 + 0 ++ 0 +
72 prcc 67.7 ++ 2   1+0N T
Extracts from 20 samples of clear cell RCC and four nonclear cell renal tumours were evaluated for the expression and function of apoptosome components (cc, clear cell; cp,
chromophobe; oc, oncocytoma; prcc, papillary/chromophilic). Numbers of samples where tumour cell purity was above 90% appear in bold. Extracts were incubated in the
absence of cytochrome c or in the presence 50mgml
 1 cytochrome c for 1h at 371C. Reactions were then tested by immunoblotting for processing of caspase-3, -7 and -9.
Relative effector caspase activity is given as percent of HeLa control (assessment of the expression and processing was carried out as in Tables 1 and 2). NT¼not tested (usually
because of limitations of material). *DEVD-cleaving activity, effect of caspase activity (see Methods).
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smaterial, all but one showed a good activation of caspases
by cytochrome c (unfortunately, we were unable to obtain
information of this one as to expression of Apaf-1 and
expression/activation of caspase-9). Caspase-3 was expressed
to a significant level in all cases, and in all cases where we were
able to test it the expression of the apoptosome components
appeared normal (the results are summarised in Table 3,
and an example of caspase processing is given in Figure 2A). It
can thus be stated that, based on the analysis of 20 primary
samples, the clear cell RCC contain a functionally competent
apoptosome.
Although the sample size was too small to arrive at a definite
conclusion, striking abnormalities were found in other entities of
renal tumours (Table3 and Figure 2). Two (benign) oncocytomas,
one chromophobe RCC and one papillary RCC could be included.
In neither oncocytoma cytochrome c activated caspases. In one
case, this defect correlated with a lack of Apaf-1 expression
(Figure 2). The chromophobe RCC lacked the expression of
caspase-9, which probably accounts for the complete absence of
cytochrome c-induced caspase activation (Figure 2). In the case of
papillary RCC (despite a nondetectable expression of caspase-7),
the induction of DEVD-cleaving activity by cytochrome c was
normal (Table 3). We conclude that at least in some cases of
nonclear cell RCC the expression of apoptosome components is
altered.
Role of IAP on cytochrome c-dependent caspase activity
Members of the family of IAPs have the capacity to inhibit
caspases. More precisely, they seem to target active caspase-9 or -3
and block its activity (Verhagen et al, 2001). A high level of
expression of various IAP can therefore inhibit apoptosis at the
level of the apoptosome and thus contribute to a resistance to
apoptotic stimuli. The activity of the known antiapoptotic IAP can
be overcome by the cellular protein Smac/DIABLO (reviewed in
Silke and Vaux, 2001). DIABLO is normally sequestered in the
mitochondria but is, like cytochrome c, released into the cytosol
during apoptosis where it then acts to relieve the block in the
apoptotic pathway imposed by IAP.
We utilised this principle to test for the possibility that a high
level of IAP contributes to apoptosis resistance in RCC. The
DIABLO protein can be functionally replaced by a synthetic
peptide corresponding to its seven N-terminal amino acids;
addition of this peptide to cell extracts has been shown to be
able to revert the inhibition of IAP (Chai et al, 2000). Since various
IAP could principally contribute to apoptosome inhibition and
mere IAP expression levels may not be as informative, we
compared the caspase activity induced by cytochrome c in the
absence and the presence of DIABLO peptide. The difference
between the two activities should correspond to the
inhibition imposed by endogenous IAP. Initial experiments with
extracts from RCC cell lines confirmed that recombinant
purified XIAP reduced the DEVD-cleaving activity induced by
cytochrome c in cell extracts. When DIABLO peptide was added,
the activity was restored indicating that the peptide indeed was
able to abolish the inhibitory activity of the added XIAP
(Figure 3A). A peptide of the same composition but the reverse
orientation had no activity (Figure 3B). To test the degree of
inhibition by endogenous IAP, we then added DIABLO peptide
together with cytochrome c to extracts from RCC. In all, 12
samples of clear cell RCC (from the above collective) were tested in
this way. In one sample, the addition of DIABLO peptide together
with cytochrome c had a somewhat enhancing effect on the
resulting DEVD-cleaving activity (Figure 3D), in the other 11
samples no effect could be detected (one example is shown in
Figure 3C). It is thus unlikely that an IAP-imposed block on
apoptosome function is a functionally important feature of clear
cell RCC.
DISCUSSION
The data presented in this study provide evidence that the
apoptosome (i.e. the caspase-activating complex that is formed
upon release of cytchrome c) is structurally and functionally
intact in cells from RCC cell lines and primary RCC, at least
when investigated by the addition of exogenous cytochrome c.
Although, with the method used, a population of totally
pure primary tumour cells could not be obtained, eight out
Patient no.
1 2 3 HeLa
− + − + − + − + Cyt c :
Caspase-3
Cyt c
Caspase-3
Caspase-9
Caspase-3
Caspase-9
Apaf-1
-actin
Apaf-1
-actin
-actin
*
Oncocytoma CP
RCC HeLa HeLa #39 #41
− + − + − ++ + −−
A
B
Figure 2 Examples of expression and processing of components of the
apoptosome in clinical samples from RCC. Cells were isolated and extracts
were prepared from fresh explants of clear cell RCC (A) or from one
chromophobe RCC and two oncocytomas (B). Extracts from HeLa cells
were prepared as above. Extracts (800mg protein in 40ml) were incubated
for 1h at 371C in the presence or absence of 50mgml
 1 cytochrome c.A
measure of 200mg per lane were run on SDS–PAGE and proteins were
detected by Western blotting. Purity of the chromophobe RCC was about
80% tumour cells, suggesting that a contamination of 20% nontumour cells
does not distort the results. (A) Asterisk denotes a nonspecific band, arrow
procaspase-9. The several bands recognised by the anti-Apaf-1 antibody
were seen in several experiments and may constitute Apaf-1 variants or, at
least in part, products of nonspecific degradation. The smaller size band in
the lane patient #3, no cytochrome c in the caspase-9 blot is of unknown
origin and was not see in any other blot.
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sof 20 samples contained over 90% of tumour cells, and this
appears as a purity that is likely high enough to obtain results
relevant to the tumour cell population. Alterations in this central
structure are therefore probably not involved in this case of
tumorigenesis or in the high level of resistance in these cells to
cytotoxic stimuli.
It has been clear for over a decade that the inhibition of
apoptosis can contribute to the development for cancer, a finding
first demonstrated in mice overexpressing both c-myc (driving the
cell cycle) and Bcl-2 (which inhibits apoptosis) in the lymphatic
system (Strasser et al, 1990). Therefore, if not inhibited, apoptosis
must occur during transformation and act to prevent tumour
development. What the precise triggers of apoptosis during
tumorigenesis are is not known. Under certain circumstances
the overexpression of oncogenes, as it would occur in arising
tumours, can trigger apoptosis (Fearnhead et al, 1997; Evan and
Littlewood, 1998), and it may be such dysregulations of cellular
functions that have to be countered by apoptosis defects. As
already mentioned, mutations in the apoptotic apparatus may also
be expected to contribute to increased resistance to radio- and
chemotherapy.
Accordingly, apoptosis deficiencies can potentially arise at any
step of the apoptotic pathway that is relevant to the initiation and
implementation of apoptosis either during tumorigenesis or
chemotherapy. The central compound of the apoptosis pathway,
the apoptosome, is a plausible candidate for a target where
mutations might have a tumour-promoting effect, although this
may apply not to all cell types. A recent study shows that a loss of
Apaf-1 or caspase-9 does not prevent apoptosis in cells of the
haematopoietic system and does not rescue the clonogenic
potential upon treatment with cytotoxic agents (Marsden et al,
2002); this means that mutations in the apoptosome are unlikely to
contribute to malignant transformation in this cell type. On the
other hand, sympathetic neurons can survive apoptosis induction
and release of cytochrome c as long as caspases are inhibited
experimentally; when the apoptotic stimulus is removed, the cells
seem able to recover their full physiological capacities (Martinou
et al, 1999). That inactivating mutations in the apoptosome can
indeed contribute to tumour development has most impressively
been demonstrated in a study that linked the loss of Apaf-1 to the
development of malignant melanoma (Soengas et al, 2001).
Whether such alterations would promote tumorigenesis in renal
cells is unknown.
A number of chromosomal alterations are known to occur with
high frequencies in RCC, such as deletions of chromosome 3p in
clear cell RCC (Presti et al, 1991), trisomy 7, and trisomy 17 in
chromophilic RCC and others (Kovacs et al, 1991). In approxi-
mately 40% of sporadic clear cell RCC, the inactivation of
the von Hippel–Lindau (VHL) tumour suppressor gene
located on chromosome 3p25 has been observed and seems to
play a major role for the development of this tumour type (Foster
et al, 1994, Gnarra et al, 1994, Brauch et al, 2000, Mandriota et al,
2002). The tumor suppressor function of VHL was further
substantiated by the finding that reintroduction in a cell line
blocked its ability to form tumours (Tamm et al, 2003). The loss of
VHL -protein again results in the dysregulation of hypoxia-
induced factor 1 (Maxwell et al, 1999; Mack et al, 2003), and this
dysregulation may affect the sensitivity of the cells to apoptotic
stimuli at least in some cell types (for a discussion of this subject
see Piret et al, 2003). Comparative studies of VHL-positive and -
negative RCC lines have found that VHL afforded a protection
against hypoxia, possibly via upregulation of Bcl-2 (Devarajan et al,
2001).
The irregularities we describe here in oncocytoma and
chromophobe RCC are interesting, but can have only anecdotal
value at this stage. Oncoytoma is considered a benign tumour. This
does not exclude the possibility that, for instance, a loss of Apaf-1
could contribute to tumour development. Likewise, the loss of
caspase-9 expression in chromophobe carcinoma may contribute
to the rise of this type of tumour, but more data are obviously
needed to confirm this initial finding.
We believe that we can say with some certainty that in clear cell
RCC the apoptosome is functionally intact. These data fail to
confirm earlier findings derived from a number of cell lines that
RCC cells have a severely reduced expression of caspases-3
(Kolenko et al, 1999). The resistance to apoptotic stimuli in RCC
cells has been documented in cell lines (Wu et al, 2000) and, as
already discussed, is likely to extend to primary tumours. Now we
have excluded the cytochrome c-dependent apparatus, we will
focus on the events at and upstream of mitochondria. A recent
comprehensive study of gene expression in RCC provides much
information about mRNA expression levels in primary tumours
(Boer et al, 2001). Although a number of ‘apoptosis-related’ genes
in that study have been found to have a changed expression in
RCC, this appears to relate largely to genes that have functions in
the broader context of apoptosis induction (i.e. proteins whose
impact on the intracellular equilibrium helps to determine the live-
or-die decision, such as k-ras (Arber et al, 1997), klotho (Nagai
et al, 2003) or thioredoxin (Baker et al, 1997)) rather than genes
whose products make up the apoptosis pathway itself (for instance,
Bcl-2-family members). It certainly remains a distinct possibility
that alterations other than a change in the expression of the intact
gene account for apoptosis defects. Small structural mutations in
critical apoptosis regulators could have profound effects on
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Figure 3 Effect of IAP on the cytochrome c-dependent generation of
effector caspase activity. Extracts were prepared from the cell lines KTCTL-
30 or CAKI-1 (top) or primary clear cell RCC (two examples are shown at
the bottom). (A and B) Extracts were incubated without cytochrome c
(open circles) or with cytochrome c (closed circles). To some samples
recombinant XIAP was added together with cytochrome c and was found
to inhibit the generation of caspase activity (squares). To evaluate the
efficacy of DIABLO peptide, one sample was incubated with cytochrome c,
XIAP and DIABLO peptide (300mM); DIABLO at least partially relieved the
inhibition by XIAP (triangles). In (B), a control peptide of the same
composition but the reverse orientation was added instead of the DIABLO
peptide (300mM; together with cytochrome c and XIAP, open triangles).
Effector caspase activity was measured as free AMC every 5min, individual
measurements are shown. (C and D) Examples of the effect of DIABLO
peptide in extracts from primary RCC. Samples from patients (#51 and
#54, see Table 3) were incubated without cytochrome c (open circles),
with cytochrome c (50mgml
 1, closed circles) or with cytochrome c plus
DIABLO peptide (300mM, filled squares). Effector caspase activity was
measured as free AMC as above.
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sapoptosis resistance. It is our belief that further functional tests in
the upstream apoptosis system are, at present, the most promising
approach to advance our understanding of the tumour’s behaviour
with reference to apoptosis. Such tests should especially include
the assessment of the resistance of mitochondria to activated BH3-
only proteins (for instance, by using recombinant proteins in
permeabilised cells); this would reveal a ‘mitochondria’ block in
the apoptotic pathway. The assessment of the activation of BH3-
only proteins upon treatment with apoptosis-inducing stimuli
(such as the induction of Noxa and Puma proteins by ionising
irradiation or the activation of Bim by UV irradiation, Huang and
Strasser, 2000) might also reveal specific defects in the signal
transduction of apoptosis.
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